
Peptide Therapeutics Forum 2023

## Designed EVH1 inhibitors derived from synthetic diproline mimetics (ProMs) rigidified in a PPII helix conformation

F. Blüm,<sup>[a]</sup> M. Barone,<sup>[b]</sup> M. Müller,<sup>[b,c]</sup> D. Albat,<sup>[a,c]</sup> S. Chiha,<sup>[a,c]</sup> R. Kühne,<sup>[b]</sup> and H.-G. Schmalz<sup>[a]</sup>

<sup>a</sup>Department of Chemistry, University of Cologne, Greinstraße 4, 50939 Köln, Germany; <sup>b</sup>Leibniz-Institut für Molekulare Pharmakologie (FMP), Robert-Roessle-Str. 10, 13125 Berlin, Germany; <sup>c</sup>PROSION GmbH, Weyertal 109, 50931 Köln, Germany

We combined computational modeling, X-ray crystallography, organic synthesis and biological investigations to develop small-molecule inhibitors for the Ena/VASP EVH1 domain, which is involved in the migration and chemotaxis (metastasis) of invasive cancer cells.<sup>[1]</sup> Using synthetic diproline mimetics such as **ProM-1**,<sup>[2a]</sup> **ProM-2**,<sup>[2b]</sup> **ProM-13**<sup>[2c]</sup> and **ProM-15**<sup>[2d]</sup> we succeeded to reduce the wild-type oligopeptide sequence **WT1** to an equivalent of the pentapeptidic proline rich core sequence **WT2**, which itself only shows weak binding. By freezing pairs of prolines in a PPII helix conformation (by formal introduction of a vinylidene bridge) in combination with the introduction of a chlorine atom to the phenylalanine residue, the first nanomolar EVH1 inhibitors (L1-L3) were obtained.<sup>[1]</sup>



Besides exhibiting strong affinity, the optimized inhibitors were shown to bind to the EVH1 domain in the canonical fashion. While *in vitro* cell migration experiments proved the inhibition of chemotaxis, the extravasation of MDA-MB-231 cancer cells was demonstrated *in vivo* using transgenic zebrafish embryos.<sup>[1b]</sup> Notably, the compounds showed high selectivity towards EVH1 in comparison to other proline-rich motif-recognizing (off-target) protein domains (Fyn SH3, Profilin, Yap1 WW1) as revealed by <sup>1</sup>H<sup>15</sup>N HSQC NMR experiments.

## **References:**

- (a) R. Opitz, M. Müller, C. Reuter *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **2015**, *112*, 5011-5016; (b) M. Barone,
  M. Müller, S. Chiha *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* **2020**, *117*, 29684–29690.
- (a) J. Zaminer, C. Brockmann, P. Huy *et al.*, *Angew. Chem. Int. Ed.* **2010**, *49*, 7111–7115; (b) C. Reuter, R. Opitz, A. Soicke *et al.*, *Chem. Eur. J.* **2015**, *21*, 8464–8470; (c) S. Chiha, A. Soicke, M. Barone *et al.*, *Eur. J. Org. Chem.* **2018**, *2018*, 455–460; (d) S. Dohmen, M. Reiher, D. Albat *et al.*, *Chem. Eur. J.* **2020**, *26*, 3049–3053.